Listed

Vir Biotechnology, Inc.

VIRNasdaqCIK 1706431HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$238.9m, Q2 FY2026
Operating income$73.5m, Q2 FY2026
Net income$80.1m, Q2 FY2026
Vir Biotechnology, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m2.6Revenue, Q3 FY2023, three months to 2023-09-30$2.6m. XBRL concept us-gaap:Revenues. 10-Q filed 2024-11-04, accession 0001628280-24-044995.Report this figure16.8Revenue, Q4 FY2023, three months to 2023-12-31$16.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure56.4Revenue, Q1 FY2024, three months to 2024-03-31$56.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-08, accession 0001628280-25-023291.Report this figure3.1Revenue, Q2 FY2024, three months to 2024-06-30$3.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-06, accession 0001628280-25-038431.Report this figure2.4Revenue, Q3 FY2024, three months to 2024-09-30$2.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure12.4Revenue, Q4 FY2024, three months to 2024-12-31$12.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure3.0Revenue, Q1 FY2025, three months to 2025-03-31$3.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-08, accession 0001628280-25-023291.Report this figure1.2Revenue, Q2 FY2025, three months to 2025-06-30$1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-06, accession 0001628280-25-038431.Report this figure0.2Revenue, Q3 FY2025, three months to 2025-09-30$240.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure64.1Revenue, Q4 FY2025, three months to 2025-12-31$64.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure(0.0)Revenue, Q1 FY2026, three months to 2026-03-31−$29.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure239Revenue, Q2 FY2026, three months to 2026-06-30$238.9m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure
Cost of revenue$m0.0Cost of revenue, Q3 FY2023, three months to 2023-09-30$38.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2024-11-04, accession 0001628280-24-044995.Report this figure0.8Cost of revenue, Q4 FY2023, three months to 2023-12-31$798.0k. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure0.1Cost of revenue, Q1 FY2024, three months to 2024-03-31$59.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-05-08, accession 0001628280-25-023291.Report this figure0.1Cost of revenue, Q2 FY2024, three months to 2024-06-30$52.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-08-06, accession 0001628280-25-038431.Report this figure0.1Cost of revenue, Q3 FY2024, three months to 2024-09-30$50.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2024-11-04, accession 0001628280-24-044995.Report this figure0.7Cost of revenue, Q4 FY2024, three months to 2024-12-31$684.0k. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure0.0Cost of revenue, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-05-08, accession 0001628280-25-023291.Report this figure0.0Cost of revenue, Q2 FY2025, three months to 2025-06-30$11.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figurenot reportednot reportednot reported0.0Cost of revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure
Research and development$m145Research and development, Q3 FY2023, three months to 2023-09-30$145.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-04, accession 0001628280-24-044995.Report this figure109Research and development, Q4 FY2023, three months to 2023-12-31$109.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure100Research and development, Q1 FY2024, three months to 2024-03-31$100.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-08, accession 0001628280-25-023291.Report this figure105Research and development, Q2 FY2024, three months to 2024-06-30$105.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-06, accession 0001628280-25-038431.Report this figure195Research and development, Q3 FY2024, three months to 2024-09-30$195.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure106Research and development, Q4 FY2024, three months to 2024-12-31$106.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure119Research and development, Q1 FY2025, three months to 2025-03-31$118.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure97.5Research and development, Q2 FY2025, three months to 2025-06-30$97.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure151Research and development, Q3 FY2025, three months to 2025-09-30$151.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure88.3Research and development, Q4 FY2025, three months to 2025-12-31$88.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure109Research and development, Q1 FY2026, three months to 2026-03-31$108.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure135Research and development, Q2 FY2026, three months to 2026-06-30$135.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure
Selling, general and administrative$m40.9Selling, general and administrative, Q3 FY2023, three months to 2023-09-30$40.9m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2024-11-04, accession 0001628280-24-044995.Report this figure41.2Selling, general and administrative, Q4 FY2023, three months to 2023-12-31$41.2m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure36.3Selling, general and administrative, Q1 FY2024, three months to 2024-03-31$36.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-05-08, accession 0001628280-25-023291.Report this figure30.3Selling, general and administrative, Q2 FY2024, three months to 2024-06-30$30.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-08-06, accession 0001628280-25-038431.Report this figure25.7Selling, general and administrative, Q3 FY2024, three months to 2024-09-30$25.7m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure26.7Selling, general and administrative, Q4 FY2024, three months to 2024-12-31$26.7m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure23.9Selling, general and administrative, Q1 FY2025, three months to 2025-03-31$23.9m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure22.3Selling, general and administrative, Q2 FY2025, three months to 2025-06-30$22.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure22.2Selling, general and administrative, Q3 FY2025, three months to 2025-09-30$22.2m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure23.6Selling, general and administrative, Q4 FY2025, three months to 2025-12-31$23.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure23.3Selling, general and administrative, Q1 FY2026, three months to 2026-03-31$23.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure30.2Selling, general and administrative, Q2 FY2026, three months to 2026-06-30$30.2m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure
Operating income$m(187)Operating income, Q3 FY2023, three months to 2023-09-30−$186.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-04, accession 0001628280-24-044995.Report this figure(139)Operating income, Q4 FY2023, three months to 2023-12-31−$139.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure(80.1)Operating income, Q1 FY2024, three months to 2024-03-31−$80.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0001628280-25-023291.Report this figure(159)Operating income, Q2 FY2024, three months to 2024-06-30−$158.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-06, accession 0001628280-25-038431.Report this figure(231)Operating income, Q3 FY2024, three months to 2024-09-30−$231.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure(117)Operating income, Q4 FY2024, three months to 2024-12-31−$117.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure(140)Operating income, Q1 FY2025, three months to 2025-03-31−$139.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure(118)Operating income, Q2 FY2025, three months to 2025-06-30−$118.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure(173)Operating income, Q3 FY2025, three months to 2025-09-30−$173.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure(47.9)Operating income, Q4 FY2025, three months to 2025-12-31−$47.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure(132)Operating income, Q1 FY2026, three months to 2026-03-31−$132.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure73.5Operating income, Q2 FY2026, three months to 2026-06-30$73.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure
Income tax$m(3.2)Income tax, Q3 FY2023, three months to 2023-09-30−$3.2m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-04, accession 0001628280-24-044995.Report this figure(4.8)Income tax, Q4 FY2023, three months to 2023-12-31−$4.8m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure0.3Income tax, Q1 FY2024, three months to 2024-03-31$276.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-08, accession 0001628280-25-023291.Report this figure(1.5)Income tax, Q2 FY2024, three months to 2024-06-30−$1.5m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-06, accession 0001628280-25-038431.Report this figure0.2Income tax, Q3 FY2024, three months to 2024-09-30$177.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure(0.1)Income tax, Q4 FY2024, three months to 2024-12-31−$86.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-03-31$16.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure0.2Income tax, Q2 FY2025, three months to 2025-06-30$170.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure0.2Income tax, Q3 FY2025, three months to 2025-09-30$168.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure(0.1)Income tax, Q4 FY2025, three months to 2025-12-31−$137.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure0.2Income tax, Q1 FY2026, three months to 2026-03-31$170.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure0.2Income tax, Q2 FY2026, three months to 2026-06-30$179.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure
Net income$m(163)Net income, Q3 FY2023, three months to 2023-09-30−$163.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-04, accession 0001628280-24-044995.Report this figure(116)Net income, Q4 FY2023, three months to 2023-12-31−$116.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure(65.3)Net income, Q1 FY2024, three months to 2024-03-31−$65.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-08, accession 0001628280-25-023291.Report this figure(138)Net income, Q2 FY2024, three months to 2024-06-30−$138.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-06, accession 0001628280-25-038431.Report this figure(214)Net income, Q3 FY2024, three months to 2024-09-30−$213.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure(105)Net income, Q4 FY2024, three months to 2024-12-31−$104.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure(121)Net income, Q1 FY2025, three months to 2025-03-31−$121.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure(111)Net income, Q2 FY2025, three months to 2025-06-30−$111.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure(163)Net income, Q3 FY2025, three months to 2025-09-30−$163.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure(42.9)Net income, Q4 FY2025, three months to 2025-12-31−$42.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure(126)Net income, Q1 FY2026, three months to 2026-03-31−$125.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure80.1Net income, Q2 FY2026, three months to 2026-06-30$80.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure
Diluted EPS$ per share(1.22)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$1.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-04, accession 0001628280-24-044995.Report this figurenot reported(0.48)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0001628280-25-023291.Report this figure(1.02)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$1.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-06, accession 0001628280-25-038431.Report this figure(1.56)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$1.56 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figurenot reported(0.88)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.88 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure(0.80)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.80 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure(1.17)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$1.17 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figurenot reported(0.85)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.85 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure0.47Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.47 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure
Basic EPS$ per share(1.22)Basic EPS, Q3 FY2023, three months to 2023-09-30−$1.22 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-04, accession 0001628280-24-044995.Report this figurenot reported(0.48)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.48 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0001628280-25-023291.Report this figure(1.02)Basic EPS, Q2 FY2024, three months to 2024-06-30−$1.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-06, accession 0001628280-25-038431.Report this figure(1.56)Basic EPS, Q3 FY2024, three months to 2024-09-30−$1.56 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figurenot reported(0.88)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.88 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure(0.80)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.80 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure(1.17)Basic EPS, Q3 FY2025, three months to 2025-09-30−$1.17 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figurenot reported(0.85)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.85 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure0.48Basic EPS, Q2 FY2026, three months to 2026-06-30$0.48 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure

Balance sheet

Cash and equivalents$278.7m, Q2 FY2026
Shareholders' equity$982.5m, Q2 FY2026
Vir Biotechnology, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m452Cash and equivalents, Q3 FY2023, at 2023-09-30$452.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-04, accession 0001628280-24-044995.Report this figure242Cash and equivalents, FY2023, at 2023-12-31$241.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-23, accession 0001628280-26-010749.Report this figure161Cash and equivalents, Q1 FY2024, at 2024-03-31$160.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0001628280-25-023291.Report this figure297Cash and equivalents, Q2 FY2024, at 2024-06-30$296.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-06, accession 0001628280-25-038431.Report this figure168Cash and equivalents, Q3 FY2024, at 2024-09-30$168.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure223Cash and equivalents, FY2024, at 2024-12-31$222.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-23, accession 0001628280-26-010749.Report this figure274Cash and equivalents, Q1 FY2025, at 2025-03-31$273.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure211Cash and equivalents, Q2 FY2025, at 2025-06-30$211.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure170Cash and equivalents, Q3 FY2025, at 2025-09-30$170.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure232Cash and equivalents, FY2025, at 2025-12-31$232.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure274Cash and equivalents, Q1 FY2026, at 2026-03-31$274.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure279Cash and equivalents, Q2 FY2026, at 2026-06-30$278.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure
Current assets$m1,769Current assets, Q3 FY2023, at 2023-09-30$1.77bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-03, accession 0001628280-23-036702.Report this figure1,588Current assets, FY2023, at 2023-12-31$1.59bn. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-27, accession 0001628280-25-008245.Report this figure1,213Current assets, Q1 FY2024, at 2024-03-31$1.21bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-03, accession 0001628280-24-020299.Report this figure1,206Current assets, Q2 FY2024, at 2024-06-30$1.21bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-01, accession 0001628280-24-034195.Report this figure1,047Current assets, Q3 FY2024, at 2024-09-30$1.05bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-04, accession 0001628280-24-044995.Report this figure1,042Current assets, FY2024, at 2024-12-31$1.04bn. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-23, accession 0001628280-26-010749.Report this figure932Current assets, Q1 FY2025, at 2025-03-31$932.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0001628280-25-023291.Report this figure736Current assets, Q2 FY2025, at 2025-06-30$735.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-06, accession 0001628280-25-038431.Report this figure546Current assets, Q3 FY2025, at 2025-09-30$545.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure514Current assets, FY2025, at 2025-12-31$514.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure523Current assets, Q1 FY2026, at 2026-03-31$523.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure574Current assets, Q2 FY2026, at 2026-06-30$573.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure
Total assets$m2,045Total assets, Q3 FY2023, at 2023-09-30$2.04bn. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-03, accession 0001628280-23-036702.Report this figure1,919Total assets, FY2023, at 2023-12-31$1.92bn. XBRL concept us-gaap:Assets. 10-K filed 2025-02-27, accession 0001628280-25-008245.Report this figure1,794Total assets, Q1 FY2024, at 2024-03-31$1.79bn. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-03, accession 0001628280-24-020299.Report this figure1,670Total assets, Q2 FY2024, at 2024-06-30$1.67bn. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-01, accession 0001628280-24-034195.Report this figure1,498Total assets, Q3 FY2024, at 2024-09-30$1.50bn. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-04, accession 0001628280-24-044995.Report this figure1,399Total assets, FY2024, at 2024-12-31$1.40bn. XBRL concept us-gaap:Assets. 10-K filed 2026-02-23, accession 0001628280-26-010749.Report this figure1,308Total assets, Q1 FY2025, at 2025-03-31$1.31bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0001628280-25-023291.Report this figure1,193Total assets, Q2 FY2025, at 2025-06-30$1.19bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-06, accession 0001628280-25-038431.Report this figure1,019Total assets, Q3 FY2025, at 2025-09-30$1.02bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure1,003Total assets, FY2025, at 2025-12-31$1.00bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure1,026Total assets, Q1 FY2026, at 2026-03-31$1.03bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure1,215Total assets, Q2 FY2026, at 2026-06-30$1.21bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure
Current liabilities$m165Current liabilities, Q3 FY2023, at 2023-09-30$165.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-03, accession 0001628280-23-036702.Report this figure175Current liabilities, FY2023, at 2023-12-31$175.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-27, accession 0001628280-25-008245.Report this figure94.1Current liabilities, Q1 FY2024, at 2024-03-31$94.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-03, accession 0001628280-24-020299.Report this figure96.4Current liabilities, Q2 FY2024, at 2024-06-30$96.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-01, accession 0001628280-24-034195.Report this figure117Current liabilities, Q3 FY2024, at 2024-09-30$117.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-04, accession 0001628280-24-044995.Report this figure120Current liabilities, FY2024, at 2024-12-31$119.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-23, accession 0001628280-26-010749.Report this figure137Current liabilities, Q1 FY2025, at 2025-03-31$137.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-08, accession 0001628280-25-023291.Report this figure105Current liabilities, Q2 FY2025, at 2025-06-30$105.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-06, accession 0001628280-25-038431.Report this figure75.2Current liabilities, Q3 FY2025, at 2025-09-30$75.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure92.8Current liabilities, FY2025, at 2025-12-31$92.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure73.6Current liabilities, Q1 FY2026, at 2026-03-31$73.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure95.0Current liabilities, Q2 FY2026, at 2026-06-30$95.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure
Total liabilities$m370Total liabilities, Q3 FY2023, at 2023-09-30$369.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-03, accession 0001628280-23-036702.Report this figure329Total liabilities, FY2023, at 2023-12-31$328.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-27, accession 0001628280-25-008245.Report this figure247Total liabilities, Q1 FY2024, at 2024-03-31$246.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-03, accession 0001628280-24-020299.Report this figure236Total liabilities, Q2 FY2024, at 2024-06-30$235.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-01, accession 0001628280-24-034195.Report this figure258Total liabilities, Q3 FY2024, at 2024-09-30$257.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-04, accession 0001628280-24-044995.Report this figure248Total liabilities, FY2024, at 2024-12-31$248.4m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-23, accession 0001628280-26-010749.Report this figure264Total liabilities, Q1 FY2025, at 2025-03-31$263.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0001628280-25-023291.Report this figure245Total liabilities, Q2 FY2025, at 2025-06-30$245.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-06, accession 0001628280-25-038431.Report this figure223Total liabilities, Q3 FY2025, at 2025-09-30$223.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure238Total liabilities, FY2025, at 2025-12-31$237.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure213Total liabilities, Q1 FY2026, at 2026-03-31$212.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure232Total liabilities, Q2 FY2026, at 2026-06-30$232.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure
Shareholders' equity$m1,675Shareholders' equity, Q3 FY2023, at 2023-09-30$1.68bn. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2024-11-04, accession 0001628280-24-044995.Report this figure1,590Shareholders' equity, FY2023, at 2023-12-31$1.59bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure1,547Shareholders' equity, Q1 FY2024, at 2024-03-31$1.55bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-06, accession 0001628280-25-038431.Report this figure1,434Shareholders' equity, Q2 FY2024, at 2024-06-30$1.43bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure1,241Shareholders' equity, Q3 FY2024, at 2024-09-30$1.24bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure1,150Shareholders' equity, FY2024, at 2024-12-31$1.15bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure1,044Shareholders' equity, Q1 FY2025, at 2025-03-31$1.04bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure947Shareholders' equity, Q2 FY2025, at 2025-06-30$947.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure796Shareholders' equity, Q3 FY2025, at 2025-09-30$796.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure765Shareholders' equity, FY2025, at 2025-12-31$765.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure813Shareholders' equity, Q1 FY2026, at 2026-03-31$812.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure982Shareholders' equity, Q2 FY2026, at 2026-06-30$982.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure

Cash flow

Operating cash flow$123.3m, Q2 FY2026
Capital expenditure$32.0k, Q2 FY2026
Vir Biotechnology, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(156)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$155.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-04, accession 0001628280-24-044995. Derived: 9-month figure less the 6-month figure.Report this figure(108)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$107.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure(109)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$109.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0001628280-25-023291.Report this figure(77.8)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$77.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-06, accession 0001628280-25-038431. Derived: 6-month figure less the 3-month figure.Report this figure(171)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$171.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001628280-25-049694. Derived: 9-month figure less the 6-month figure.Report this figure(87.6)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$87.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure(78.1)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$78.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure(120)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$120.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001628280-26-053549. Derived: 6-month figure less the 3-month figure.Report this figure(168)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$167.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001628280-25-049694. Derived: 9-month figure less the 6-month figure.Report this figure(25.9)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$25.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure(132)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$132.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure123Operating cash flow, Q2 FY2026, three months to 2026-06-30$123.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001628280-26-053549. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m3.7Capital expenditure, Q3 FY2023, three months to 2023-09-30$3.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-04, accession 0001628280-24-044995. Derived: 9-month figure less the 6-month figure.Report this figure1.5Capital expenditure, Q4 FY2023, three months to 2023-12-31$1.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure1.9Capital expenditure, Q1 FY2024, three months to 2024-03-31$1.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-08, accession 0001628280-25-023291.Report this figure0.7Capital expenditure, Q2 FY2024, three months to 2024-06-30$666.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-06, accession 0001628280-25-038431. Derived: 6-month figure less the 3-month figure.Report this figure2.8Capital expenditure, Q3 FY2024, three months to 2024-09-30$2.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001628280-25-049694. Derived: 9-month figure less the 6-month figure.Report this figure2.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$2.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure1.6Capital expenditure, Q1 FY2025, three months to 2025-03-31$1.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure2.5Capital expenditure, Q2 FY2025, three months to 2025-06-30$2.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001628280-26-053549. Derived: 6-month figure less the 3-month figure.Report this figure0.3Capital expenditure, Q3 FY2025, three months to 2025-09-30$317.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001628280-25-049694. Derived: 9-month figure less the 6-month figure.Report this figure0.3Capital expenditure, Q4 FY2025, three months to 2025-12-31$348.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-23, accession 0001628280-26-010749. Derived: 12-month figure less the 9-month figure.Report this figure0.4Capital expenditure, Q1 FY2026, three months to 2026-03-31$390.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$32.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001628280-26-053549. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)168.88m, Q2 FY2026
Vir Biotechnology, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares135Diluted shares (weighted), Q3 FY2022, three months to 2022-09-30134,963,317 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-03, accession 0001628280-23-036702.Report this figure134Diluted shares (weighted), Q1 FY2023, three months to 2023-03-31133,552,839 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-03, accession 0001628280-24-020299.Report this figure134Diluted shares (weighted), Q2 FY2023, three months to 2023-06-30134,059,079 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-01, accession 0001628280-24-034195.Report this figure134Diluted shares (weighted), Q3 FY2023, three months to 2023-09-30134,289,620 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-04, accession 0001628280-24-044995.Report this figure135Diluted shares (weighted), Q1 FY2024, three months to 2024-03-31135,280,648 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0001628280-25-023291.Report this figure136Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30136,223,725 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-06, accession 0001628280-25-038431.Report this figure137Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30136,653,753 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure137Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31137,468,900 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure138Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30138,447,469 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure139Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30138,930,173 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001628280-25-049694.Report this figure147Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31147,356,811 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001628280-26-031471.Report this figure169Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30168,879,127 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure

Shares outstanding: 169.22mShares outstanding, period not labelled, at 2026-07-29169,215,958 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-05, accession 0001628280-26-053549.Report this figure at Jul 29, 2026, from the cover of the 10-Q filed Aug 5, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. Listed shows no prices and gives no investment advice.